Carmell Announces Successful Closing of $3.0 Million Private Placement
- None.
- None.
Insights
The recent private placement by Carmell Corporation signifies a strategic move to bolster its financial health and support the commercial launch of its product pipeline. The $3 million in gross proceeds, although not substantial for a biotech firm, provides the necessary capital to fund ongoing operations and research endeavors. The pricing strategy, with a discount for investors other than the CEO, is a common incentive in private placements to attract capital. However, the discount rate should be analyzed in the context of the company's valuation and investor confidence.
Investors should consider the dilutive effect of the additional shares on the market, which now total around 20.58 million. It's essential to monitor the company's subsequent earnings reports and any announcements regarding the use of the raised funds. The performance of the 10 products mentioned by the CEO will be a important factor in evaluating the long-term return on this investment. Financial stakeholders should scrutinize the company's ability to execute its commercialization strategy and the market potential of its anti-aging bio-aesthetics technology.
The anti-aging market is witnessing significant growth, driven by an increasing global population of elderly individuals and a rising demand for products that can delay signs of aging. Carmell Corporation's focus on revolutionary anti-aging bio-aesthetics technology places it in a competitive but lucrative market. The investor confidence shown through the private placement could be indicative of the market's belief in the potential of Carmell's pipeline of 10 products.
Understanding the competitive landscape, including key players, market size and growth projections, is vital for stakeholders. The success of Carmell's commercial launch efforts will depend on its ability to differentiate its offerings and penetrate the market effectively. The impact on the stock market will be closely tied to consumer reception of these new products and the company's marketing prowess. Market trends, consumer preferences and regulatory changes in the bio-aesthetics industry will also play a significant role in shaping the company's future.
Biotech firms like Carmell Corporation often require substantial capital to fund research and development before reaching profitability. The closing of this private placement is a critical step in securing the financial runway needed for product development and commercialization. The mention of a 'revolutionary' technology by the CEO suggests a potential for disruptive innovation in the skin and hair health sector.
Investors should assess the scientific credibility and potential market impact of Carmell's technology. The biotech industry is known for its high-risk, high-reward nature and Carmell's success hinges on its ability to translate its bio-aesthetics technology into commercially viable products. Regulatory hurdles, clinical trial outcomes and intellectual property rights are additional factors that can significantly influence the company's trajectory and should be monitored by stakeholders.
PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “Private Placement”). The Company received gross proceeds from the Private Placement of
The Company issued and sold an aggregate amount of 1,331,452 shares of its common stock upon the closing of the Private Placement at a price of
Following the closing of the Private Placement, Carmell will have approximately 20.58 million shares of common stock outstanding.
Said Mr. Rajiv Shukla, Chairman & CEO of Carmell, “We are grateful for the faith and support of our investors as we scale up our commercial launch efforts around our pipeline of 10 products built on a foundation of revolutionary anti-aging bio-aesthetics technology.”
Brookline Capital Markets, a division of Arcadia Securities, LLC, served as the exclusive placement agent for the private placement transaction.
About Carmell
Carmell is a bio-aesthetics company that utilizes the Carmell Secretome™ to support skin and hair health. The Carmell Secretome™ consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past 7 years, the Company has extensively tested the technology underpinning the Carmell Secretome™. Additionally, the Company has developed a novel microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen™, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Carmell’s microemulsion formulations do not utilize mineral or vegetable oils and are designed to be non-comedogenic. The Company is also developing a line of men’s products and a line of topical haircare products. All products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. For more information, visit www.carmellcosmetics.com.
About Private Placement
The offer and sale of the shares of common stock sold in the Private Placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and other applicable securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of its common stock sold in the Private Placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements the launch and commercialization of our products, the impact of the Private Placement on the outstanding shares of our common stock and the execution of our business strategy. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by Carmell with the SEC on April 1, 2024, and in our other reports filed with the SEC. Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Bryan Cassaday
bc@carmellcorp.com
FAQ
What is the ticker symbol of Carmell mentioned in the press release?
How much did Carmell raise in the private placement?
How many shares of common stock were issued by Carmell in the private placement?
At what price were the shares of common stock sold to the CEO in the private placement?
Who served as the exclusive placement agent for the private placement transaction of Carmell ?
